Gilead SciencesNASDAQ: GILD

Gilead Sciences, Inc. (NASDAQ:GILD ) 2024 Jefferies London Healthcare Conference November 20, 2024 4:30 AM ET Company Participants Dan O'Day - Chairman and CEO Andy Dickinson - CFO Conference Call Participants Michael Yee - Jefferies Michael Yee I'm Michael Yee, senior biotechnology analyst at Jefferies. And very pleased to have up on the front of this stage here with us the management team from Gilead.

On Friday, Gilead Sciences, Inc. (GILD) shared results from a two-and-a-half-year interim analysis of the ongoing Phase 3 ASSURE study. This study is looking at the long-term effectiveness and safety of Livdelzi.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) has shared results from a two-and-a-half-year interim analysis of the ongoing Phase 3 ASSURE study. The findings revealed that 81% of participants with primary biliary cholangitis (PBC) who received Livdelzi® (seladelpar) showed a significant biochemical response, indicating important progress in managing the disease. Furthermore, 41% of the participants were able to return to normal levels.

Investors frequently depend on analyst recommendations when choosing to buy, sell, or keep a stock. Changes in ratings from these analysts, who work for brokerage firms, can impact a stock's price, but how significant are they really?

Gilead (GILD) has recently caught the attention of Zacks.com users. Therefore, it's important to look into what the future holds for this stock.

Gilead Sciences, a major biopharmaceutical company, has announced that it will close its office located in the Eastlake area of Seattle, as confirmed to GeekWire on Wednesday.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company with over thirty years of medical advancements, has announced the pricing of senior unsecured notes totaling $3.5 billion in a public offering. This includes $750 million in 4.80% senior notes that will mature in 2029, along with $1 billion in 5.10% senior notes maturing in 2035, and another $1 billion in 5.50% senior notes.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) has shared new research findings from its advanced HIV treatment options and future developments. This includes a wide variety of data on both experimental and available medications, showcasing different dosing schedules and ways to administer them. The main results presented at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2024) highlight a groundbreaking portfolio and a promising pipeline for the future.

Gilead Sciences, Inc. saw its stock drop in early 2024 because of issues with its product development and disappointing forecasts, but it has recently bounced back significantly. The company still depends heavily on its HIV products, and good news about its pipeline and stronger-than-expected results have led to a 50% increase in shares since summer. However, I remain cautious because of slower growth in oncology and the stock's current momentum, even though its valuations seem reasonable at 13 times adjusted earnings.